The UK and US have established a significant bilateral deal that will ensure zero import taxes on British pharmaceutical shipments going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these key goods will be held at zero for a period of 36 months.
This agreement is in response to previous warnings to hike import taxes on branded drug imports, with potential rates discussed up to double the cost.
"This agreement with the UK reinforces the international landscape for innovative medicines and establishes much-needed equity to transatlantic drug exports," an announcement noted.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the United States, which is clearly the largest buyer for leading UK drugmakers.
Export figures indicate that in the one-year period leading up to last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This amount represented a significant portion of British export trade in that period.
"This agreement secures employment, stimulates funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a government official stated.
Detailed British Pledges
The deal entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at 15%. Last year, rebates were more than twenty percent.
Industry Background
The pact follows a ongoing row between the sector and the UK government over medicine costs and regulatory access.
The disagreement were exacerbated by claims that American patients were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or cancelled, while substantial investments have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
